证券日报网讯 海特生物10月13日在互动平台回答投资者提问时表示，公司目前经营正常，半年度业绩 仍为亏损，具体可详见公司公告，全年情况后续可关注公司的定期报告。根据《深圳证券交易所创业板 股票上市规则》的相关规定，公司目前不存在触及ST风险的情形。未来公司会全力推进注射用埃普奈 明的上市销售工作，提高产品的市场占有率。同时公司也会积极拓展创新药研发管线，持续加大在创新 药研发领域的投入力度，为公司未来发展储备更多的创新药物产品。 （编辑 袁冠琳） ...

6月12日，"提质增效强信心 稳中求进促发展"——湖北辖区上市公司2025年投资者集体接待日活动暨 2024年度业绩说明会活动在全景路演成功举办。 湖北海报.jpg 了解更多公司与投资者交流互动详情，请点击：https://rs.p5w.net/html/147922.shtml 海特生物（300683）在与投资者互动交流环节，就公司重磅产品市场化推广进展有关情况的提问，公司 方面介绍称：埃普奈明作用机靶点（DR4和DR5）不同于已上市的抗肿瘤药物，同靶点药物目前国内外 均无上市， 具有独特的作用机制，为患者提供新的治疗方案。 公司方面指出：已有相关临床前研究表明，注射用埃普奈明可能通过影响免疫微环境的方式，对接受 CAR-T细胞回输的患者体内的CAR-T细胞扩增产生积极影响，且由于注射用埃普奈明起效迅速、安全性 良好等特点，正在越来越多的进入到国内主流的血液病医院的CAR-T治疗过程中，而包括中国医学科学 院血液病医院、西部战区总医院在内的国内一线血液病医院也在积极与我司合作开展埃普奈明用于 CAR-T前桥接化疗及CAR-T后的维持治疗等方向的临床试验研究。 公司表示，将加大推进新药商业化进程，集中资源与精 ...

Group 1: Investor Relations Activity - The investor relations activity was conducted online on June 12, 2025, from 14:30 to 16:50 [2] - The event was hosted on the "Investor Relations Interactive Platform" [2] - Company representatives included Secretary of the Board Yang Kun and Financial Director Xian Wen [2] Group 2: Product Pipeline and Clinical Research - The company has not increased its investment in Zhongmu Medical despite its FDA breakthrough therapy status [3] - The injection of Epinavine is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least two prior systemic therapies [3] - Epinavine is increasingly being integrated into CAR-T treatment protocols in major hospitals [5] Group 3: Future Development and Goals - In 2025, the company aims to enhance its market share for Epinavine and expand its CRO and CDMO services [6][7] - The company plans to continue developing its innovative drug pipeline and improve project management for R&D [7] - Epinavine has been included in the national medical insurance directory since 2024, with sales expected to progress smoothly [12] Group 4: Market Position and Competitive Advantage - Epinavine targets unique mechanisms (DR 4 and DR 5) not currently addressed by existing anti-tumor drugs, providing new treatment options [9] - The company is actively pursuing new indications and combination therapies for Epinavine [9] - The sales of the company's other product, mouse nerve growth factor, have declined since its removal from the national medical insurance directory in 2019, but the market is stabilizing [10]

Group 1: Company Performance - The company achieved a revenue of 157 million yuan in Q1 2025, representing an 18.79% year-on-year increase [3] - The net profit attributable to the parent company was approximately -13.93 million yuan, an increase of 15.81% year-on-year [3] - The operating cash flow net amount dropped significantly by 644.52% year-on-year [2] Group 2: R&D and Product Development - The company is focused on improving R&D efficiency by establishing a comprehensive project management system and optimizing the R&D structure [2] - The new drug Epinavim is expected to be officially launched in May 2024 and will enter the national medical insurance directory, becoming a new profit growth point [2] - The company is actively promoting Epinavim's market entry and has received export sales certification [3] Group 3: Financial Strategy and Shareholder Relations - The company distributed approximately 17 million yuan in mid-year dividends for 2024, despite a net loss of about 69 million yuan for the year [6] - The management is committed to maximizing shareholder interests and improving operational performance [6] - The company plans to enhance competitiveness through product differentiation and cost control strategies [4] Group 4: Industry Outlook - The biopharmaceutical industry is experiencing continuous growth, with no signs of overcapacity or technological decline [2] - The company aims to maintain its market share and improve sales through direct sales and partnerships with professional promoters [5]

Group 1 - The biopharmaceutical industry is a rapidly growing strategic emerging industry globally, with significant government support and innovation driving its development [5][7] - The global biopharmaceutical market grew from $261.1 billion in 2018 to $363.8 billion in 2022, with a compound annual growth rate (CAGR) of 8.6%, and is expected to reach $783.2 billion by 2030, with a CAGR of approximately 10.1% from 2022 to 2030 [5] - In China, the biopharmaceutical market is projected to grow from $45.2 billion in 2019 to $66.5 billion in 2023, with a CAGR of 10.13%, and is expected to reach $162.8 billion by 2030, with a CAGR of approximately 13.64% from 2023 to 2030 [7] Group 2 - The company specializes in the production and sales of biopharmaceuticals, including the first commercialized nerve growth factor product, Jinlujie, which has been widely used in clinical applications for nerve injury repair [15][16] - The company’s subsidiary, Tianjin Hankan, is a well-known CRO-CDMO integrated service provider, offering a comprehensive range of drug development services from research to clinical trials and production [11][22] - The company has developed over 200 products for more than 600 enterprises, with significant achievements in the development of generic drugs and innovative drugs [12][11] Group 3 - The company has received various accolades, including being recognized as a "National Specialized and New 'Little Giant' Enterprise" and ranking among the top 50 innovative enterprises in the pharmaceutical industry [13] - The company’s product pipeline includes innovative drugs such as injection of Epinavamine, a targeted anti-tumor drug, and other pharmaceutical products that address various medical needs [17][18][20] - The company has made significant advancements in drug registration, with several products receiving approval from the National Medical Products Administration [37]